At a glance
- Originator Abbott Laboratories
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 14 Mar 2001 Discontinued-Preclinical for Parkinson's disease in USA (Unknown route)
- 05 Oct 1998 No-Development-Reported for Parkinson's disease in USA (Unknown route)
- 22 Nov 1995 Preclinical development for Parkinson's disease in USA (Unknown route)